One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-na ïve neovascular age-related macular degeneration

ConclusionsA loading phase treatment followed by a TAE regimen with intravitreal faricimab appears to be generally safe and effective for improving visual acuity and ameliorating exudative changes in eyes with nAMD. However, there might be cases in which exudative changes cannot be adequately controlled with injections of faricimab every 8 weeks in the maintenance phase.
Source: Japanese Journal of Ophthalmology - Category: Opthalmology Source Type: research